**Acute Myelogenous Lymphoma (AML)**

- **Advanced Disease**
  - Matched Related or Unrelated Donor
    - **BMT342**
      - Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
      - PI: Johnston Fred Hutchinson
      - PI: Meyer Orca Biosystems
    - **BMT343**
      - Phase Ib T-Cell-Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
      - PI: Johnston Fred Hutchinson
      - PI: Meyer Orca Biosystems
    - **BMT345**
      - Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
      - PI: Meyer Stanford
    - **BMT346**
      - Phase I/II JSP191 + Reduced Conditioning Regimen in LowDose RT & Fludarabine in MDS/AML Undergoing HCT
      - PI: Muffy Jasper Therapeutics

- **First(CR1) or Higher Remission**
  - Mismatched Unrelated
    - **BMT377**
      - Phase Ib / III in Advanced Hematologic Malignancies Undergoing Allogeneic HCT with Either Orca-T & a T-Cell-Depleted Graft w/ Additional Infusion of Conventional T Cells & Regulatory T Cells, or SoC Allogeneic Graft
      - PI: Meyer Orca Orca Biosystems Inc.
    - **BMT391**
      - Phase II HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide in Hematologic Malignancies
      - PI: Arai Swanson Stanford National Marrow Donor Program (NMDP)
  - Matched Related or Unrelated Donor
    - **BMT338**
      - Phase I DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
      - PI: Meyer Orca Biosystems
    - **BMT339**
      - Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&AL
      - PI: Lowsky Stanford
    - **BMT333_EXP**
      - Phase III Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies
      - PI: Rezvani Gamida Cell